Thalidomide likewise suppresses clinical activity of systemic onset juvenile RA [45], and leads to monocyte apoptosis in vitro through actions on AKT-1 [46] and NF-κB signaling [47], but with the attendant threat of teratogenesis and other serious off-target effects. This evidence concerns the gene AKT1 and rheumatoid arthritis.